|Articles|November 15, 2001
- BioPharm International-11-01-2001
- Volume 14
- Issue 11
Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study
Author(s)Steven Ford, William E. Tente
by Steven Ford and William E. Tente Chimeric Therapies, Inc. Experience shows that murine MAbs used in cell therapy manufacturing can be produced with safety concerns in mind. In such cases, adequate characterization ensures that they retain functional integrity.
Advertisement
Articles in this issue
almost 24 years ago
Business Matters: Eclipsed by Catastrophealmost 24 years ago
Designs for Bioassays with Plate Location Effectsalmost 24 years ago
Liposomes (a Review), Part One: Manufacturing Issuesalmost 24 years ago
Simplifying Pharmacologic Analysis with Programmable Scientific Softwarealmost 24 years ago
Outsourcing Outlook: Truth in OutsourcingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
